USES OF IL-12 IN HEMATOPOIESIS
4 Assignments
0 Petitions
Accused Products
Abstract
Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hernatopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state. Other methods include administering IL-12 to ameliorate various hematopoietic deficiencies. Still other methods are directed to uses of IL-12 for in-vivo proliferation of hematopoietic repopulating cells, hematopoietic progenitor cells and hematopoietic stem cells. Other disclosed methods are directed to uses of IL-12 for bone marrow preservation or recovery.
-
Citations
149 Claims
-
1-118. -118. (canceled)
-
119. A method for protecting or restoring hematopoiesis or enhancing peripheral blood cell counts in a mammal having a hematopoietic cell disorder, a virus infection, or a combination thereof, wherein the method comprises:
-
(a) administering a treatment to the mammal, wherein the treatment targets the hematopoietic cell disorder, a virus infection, or a combination thereof and has an associated hematopoietic toxicity; and (b) administering one or more therapeutically effective dose(s) of IL-12 near the time of administration of the treatment, wherein the administration of IL-12 to the mammal reduces the hematopoietic toxicity of the treatment. - View Dependent Claims (120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135)
-
-
136. A method for protecting or restoring hematopoiesis or enhancing peripheral blood cell counts in a mammal having a solid tumor, wherein the method comprises:
-
(a) administering a treatment to the mammal, wherein the treatment targets the solid tumor and has an associated hematopoietic toxicity, and wherein the treatment is selected from the group consisting of radiation therapy or a combination of chemotherapy and radiation therapy; and (b) administering one or more therapeutically effective dose(s) of IL-12 near the time of administration of the treatment, wherein the administration of IL-12 to the mammal reduces the hematopoietic toxicity of the treatment. - View Dependent Claims (137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149)
-
Specification